伊利替康
中文名称 | 伊利替康 |
---|---|
中文同义词 | 盐酸依列替康;盐酸依列替康 盐酸伊立替康;盐酸伊立替康 (拓普替康);伊立替康盐酸盐;盐酸依利替康;伊利替康;盐酸伊立替康97682-44-5;盐酸伊利替康 |
英文名称 | Irinotecan hydrochloride |
英文同义词 | 7-ethyl-10-(4-(1-piperidino)-1-piperidino)carbonyloxycamptothecinhydrochlor;Irinotecan hydrochloride (S)-[1,4'-Bipiperidine]-1'-carboxylic acid, 4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester hydrochloride;(S)-4,11-Diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-9-yl ester monohydrochloride trihydrate;Camptothecin 11;U 101440E;(S)-[1,4'-Bipiperidine]-1'-carboxylic acid, 4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester hydrochloride;[1,4’-Bipiperidine]-1’-carboxylic Acid (4S)-4,11-Diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3’,4’:6,7]indolizino[1,2-b]quinolin-9-yl Ester Hydrochloride Trihydrate;CTP-11 |
CAS号 | 100286-90-6 |
分子式 | C33H39ClN4O6 |
分子量 | 623.15 |
EINECS号 | 600-054-0 |
相关类别 | 生化试剂;中药对照品;医药中间体;原料药;标准品;酶与辅酶;医药原料;喜树碱的衍生物;盐酸伊立替康;抗肿瘤药;小分子抑制剂;抗肿瘤类;Active Pharmaceutical Ingredients;Antineoplastic;Antitumors for Research and Experimental Use;Biochemistry;Chiral Reagents;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Irinotecan;API;植物提取物;Anti-cancer&immunity;抗肿瘤;精细化工;对照品-中药对照品;标准品 -中药标准品;药物杂质及中间体;医药原料药;原料;半合成水溶性喜树碱的衍生物;化工中间体;有机中间体 |
Mol文件 | 100286-90-6.mol |
结构式 | ![]() |
伊利替康 性质
熔点 | 250-256°C (dec.) |
---|---|
沸点 | 257 °C |
折射率 | 67.7 ° (C=1, H2O) |
储存条件 | 2-8°C |
溶解度 | Soluble in DMSO or DMF at approximately 20mg/ml. Sparingly soluble in aqueous buffers. /n |
形态 | 黄色粉末 |
颜色 | 白色至黄色 |
水溶解性 | Soluble in DMSO at 100mg/ml. Soluble in water at 25mg/ml with warming |
Merck | 5091 |
CAS 数据库 | 100286-90-6(CAS DataBase Reference) |
Topoisomerase I
|
Irinotecan hydrochloride is a topoisomerase I inhibitor. Irinotecan inhibits the growth of LoVo and HT-29 cells, with IC 50 s of 15.8 ± 5.1 and 5.17 ± 1.4 μM, respectively, and induces similar amounts of cleavable complexes in both in LoVo and HT-29 cells. Irinotecan suppresses the proliferation of human umbilical vein endothelial cells (HUVEC), with an IC 50 of 1.3 μM.
Irinotecan (CPT-11, 5 mg/kg) significantly inhibits the growth of tumors by intratumoral injection daily for 5 days, on two consecutive weeks in rats, and such effects also occur via continuous intraperitoneal infusion by osmotic minipump into mice. However, Irinotecan (10 mg/kg) shows no effect on the growth of tumor by i.p. Irinotecan (CPT-11, 100-300 mg/kg, i.p.) apparently suppresses tumor growth of HT-29 xenografts in athymic female mice by day 21. The two groups of Irinotecan (125 mg/kg) plus TSP-1 (10 mg/kg per day) or Irinotecan (150 mg/kg) in combination TSP-1 (20 mg/kg per day) are nearly equally effective and inhibit tumor growth 84% and 89%, respectively, and both are more effective than Irinotecan alone at doses of 250 and 300 mg/kg.
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/08/19 | HY-16562A | 盐酸伊立替康 Irinotecan hydrochloride | 100286-90-6 | 50mg | 650元 |
2024/08/19 | HY-16562A | 盐酸伊立替康 Irinotecan hydrochloride | 100286-90-6 | 10mM * 1mLin DMSO | 715元 |